0 results for 'Eli Lilly'
TV Legal Ads Proving Useful Radar for Next Big Mass Tort Categories
Tracking television legal ads that solicit plaintiffs for mass torts can give general counsel early warning of new trends and gauge the plaintiffs' bar's appetite in product litigation categories.Despite Cuts, Fenwick Sees Revenue Growth and Remains Bullish on Tech Business Bounceback
"Some uncertainty remains. But it will come back, and come back stronger," said firm chair Richard Dickson about the firm's scope of work. "We just don't know exactly when."Social Media Ads Inject New Angle in Ozempic Cases: 'It's Going to Be a Huge Focus'
The proliferation of advertising on social media for Ozempic and related drugs will be a key part of the lawsuits against Novo Nordisk and Eli Lilly.Don't Be Cranky and Don't Cause Delays: Judge Pushes for Efficiency in Ozempic MDL
"What I want is to avoid asking for continuances and asking for delay and asking for new dates. Just pick your poison and stick with it," Pratter told the approximately 70 people gathered in her courtroom Thursday.View more book results for the query "Eli Lilly"
Weight-Loss-Drug Craze Pumps Up Pay for Lilly GC
Anat Hakim joined Lilly in 2020, just before the company's stock began a long ascent that has more than quadrupled its value—pushing the company's market capitalization past Tesla's.Elanco Hires GC Just as Activist Investor Calls for CEO's Ouster
Shiv O'Neill's first high-stakes task will be helping the company navigate its relationship with Ancora Capital.Finnegan, Recovering From Earlier Revenue Losses, Sees 6% Top-Line Growth
The firm has been investing in "adjacent services" that complement its traditional core IP offerings, said managing partner Erika Arner.Treatment of Antibody Claims In the U.S. After 'Amgen v. Sanofi'
The future of antibody claiming in the United States is uncertain following the U.S. Supreme Court's ruling in 'Amgen Inc. v. Sanofi,' a highly anticipated decision concerning enablement and whether the traditional way to claim antibodies — claiming antibodies by their function — will survive as a valid claiming strategy.Judge Rejects Class Action Claim Filed Against Novo Nordisk, Eli Lilly and Sanofi-Aventis
"Plaintiffs have not sufficiently shown they failed to receive the benefit of the bargain as they have not alleged that they had 'a reasonable belief about the product induced by a misrepresentation'—and in fact they have asserted the opposite, that their ascertainable loss theory is not based on misrepresentation—or that they were misled into buying insulin that was worth less than was promised," Judge Brian R. Martinotti said.Download Now
Download Now
Download Now
Download Now